What is Zacks Small Cap's Estimate for TNXP Q1 Earnings?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) - Research analysts at Zacks Small Cap issued their Q1 2025 earnings estimates for shares of Tonix Pharmaceuticals in a research note issued to investors on Thursday, April 3rd. Zacks Small Cap analyst D. Bautz expects that the company will earn ($3.37) per share for the quarter. The consensus estimate for Tonix Pharmaceuticals' current full-year earnings is ($1,762.50) per share. Zacks Small Cap also issued estimates for Tonix Pharmaceuticals' Q2 2025 earnings at ($12.49) EPS, Q3 2025 earnings at ($4.49) EPS, Q4 2025 earnings at ($5.03) EPS, FY2025 earnings at ($16.43) EPS and FY2026 earnings at ($7.80) EPS.

Several other equities analysts have also recently issued reports on the company. Noble Financial reaffirmed an "outperform" rating and set a $70.00 price objective on shares of Tonix Pharmaceuticals in a report on Thursday, March 20th. StockNews.com began coverage on Tonix Pharmaceuticals in a research note on Monday, February 10th. They set a "sell" rating on the stock.

Tonix Pharmaceuticals Price Performance

Tonix Pharmaceuticals stock traded down $0.61 during midday trading on Monday, reaching $17.30. The company's stock had a trading volume of 717,058 shares, compared to its average volume of 750,169. The firm has a market capitalization of $111.33 million, a PE ratio of 0.00 and a beta of 1.50. Tonix Pharmaceuticals has a fifty-two week low of $6.76 and a fifty-two week high of $672.00. The stock's 50 day simple moving average is $15.10 and its 200 day simple moving average is $20.37. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($9.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($6.23) by ($3.54). Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The firm had revenue of $2.58 million for the quarter, compared to analysts' expectations of $3.20 million.

Institutional Investors Weigh In On Tonix Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Commonwealth Equity Services LLC acquired a new position in shares of Tonix Pharmaceuticals during the 4th quarter valued at $40,000. Two Sigma Investments LP bought a new position in Tonix Pharmaceuticals during the fourth quarter worth $66,000. PFG Investments LLC bought a new stake in shares of Tonix Pharmaceuticals during the 4th quarter valued at about $72,000. Northern Trust Corp acquired a new stake in shares of Tonix Pharmaceuticals during the 4th quarter worth approximately $162,000. Finally, Rhumbline Advisers acquired a new stake in Tonix Pharmaceuticals in the first quarter worth $244,000. Hedge funds and other institutional investors own 82.26% of the company's stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.